Independence Bank of Kentucky Has $339,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Independence Bank of Kentucky decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,213 shares of the medical equipment provider’s stock after selling 1,141 shares during the period. Independence Bank of Kentucky’s holdings in Zimmer Biomet were worth $339,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. raised its position in shares of Zimmer Biomet by 12.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,080 shares of the medical equipment provider’s stock worth $877,000 after purchasing an additional 881 shares during the period. Quarry LP acquired a new stake in Zimmer Biomet during the 2nd quarter worth approximately $53,000. EP Wealth Advisors LLC lifted its stake in Zimmer Biomet by 10.5% in the second quarter. EP Wealth Advisors LLC now owns 2,358 shares of the medical equipment provider’s stock valued at $256,000 after buying an additional 225 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $1,677,000. Finally, Czech National Bank increased its position in shares of Zimmer Biomet by 5.8% during the third quarter. Czech National Bank now owns 41,486 shares of the medical equipment provider’s stock worth $4,478,000 after acquiring an additional 2,282 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.1 %

ZBH opened at $109.36 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $107.94 and its 200 day simple moving average is $108.26. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The stock has a market cap of $21.77 billion, a PE ratio of 20.79, a price-to-earnings-growth ratio of 1.90 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the company posted $1.65 EPS. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ZBH shares. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Oppenheimer reduced their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Raymond James dropped their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Wells Fargo & Company upped their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.